In another trial with a similar design (NCT02261714), low or high doses of the KRAS mutation peptide TG01, consisting of seven well-known oncogenic mutations in codons G12 and G13, were used as vaccines, co-administrated with granulocyte-macrophage colony-stimulating factor (GM-CSF) in order to enhance T cell response, in 32 stage I or II pancreatic adenocarcinoma patients who had undergone surgical resection (R0 or R1) and of whom 93.75 % harbored a detectable KRAS mutation. Here, CSF2 is linked to pancreatic adenocarcinoma.